Immersion Marshall test results. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Fatigue life under different stress ratios. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Freeze–thaw splitting test results. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Preparation flowchart of ZM-modified asphalt. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Immersion Marshall test equipment and specimens. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Strength test results of semi-circular specimens. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Bending test results of beam specimens. by Yining Wang (432154)

“…Experimental results show that the ZM modifier significantly improves the dynamic stability and rutting resistance of the mixture, with dynamic stability increasing to 5245 and rut depth decreasing to 2.26 mm at a dosage of 0.5%. …”

Cardiovascular-kidney-metabolic syndrome-related Age-Adjusted Mortality Rates per 1,000,000, Stratified by age groups in Adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Cardiovascular-kidney-metabolic syndrome-related Age-Adjusted Mortality Rates per 1,000,000, Stratified by Census Regions in Adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Cardiovascular-kidney-metabolic syndrome-related Age-Adjusted Mortality Rates per 1,000,000, Stratified by ethnoracial groups in Adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

RTA408 significantly reduces RGCs loss. by Hongmei Qian (538647)

Subjects:

Fig 3 - by Razieh Bidhendi-Yarandi (7139387)

Subjects:

The results of the subgroup and meta-regression analyses, stratified by follow-up duration, age, gender, study design, and study setting. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Characteristics of studied included. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Flowchart of the search process. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Results of random effect meta-analysis using Freeman-Tukey double arcsine transformation for proportions, regardless of the duration of their symptoms. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Average ratio of the concentrations obtained with qPCR, before and after DNase treatment, and with DAO before DNase treatment of the ISP phage stocks. by Saar Van Overfelt (20378458)

Subjects:

Average concentration of the ISP phage stocks obtained with qPCR, before and after DNase treatment, and with the DAO method before the DNase treatment. by Saar Van Overfelt (20378458)

Subjects: